Scarica l'app Stockscreener
1.29
15.18%
0.17
Dopo l'orario di chiusura:
1.25
-0.04
-3.10%
Precedente Chiudi:
$1.12
Aprire:
$1.14
Volume 24 ore:
929.13K
Relative Volume:
3.11
Capitalizzazione di mercato:
$40.24M
Reddito:
$1.05M
Utile/perdita netta:
$-48.82M
Rapporto P/E:
-0.7088
EPS:
-1.82
Flusso di cassa netto:
$-47.49M
1 W Prestazione:
+4.88%
1M Prestazione:
-7.19%
6M Prestazione:
-82.91%
1 anno Prestazione:
-72.26%
Intervallo 1D:
$1.125
$1.29
Intervallo di 1 settimana:
$1.10
$1.29
Portata 52W:
$1.10
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Nome
Actinium Pharmaceuticals Inc
Settore
Industria
Telefono
646-767-3870
Indirizzo
275 Madison Avenue, 7th Floor, New York, NY
Confronta ATNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.29 | 40.24M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-08-25 | Iniziato | B. Riley Securities | Buy |
| 2020-11-05 | Iniziato | Alliance Global Partners | Buy |
| 2017-12-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | Ripresa | ROTH Capital | Buy |
| 2017-09-14 | Iniziato | Maxim Group | Buy |
| 2016-08-25 | Iniziato | ROTH Capital | Buy |
| 2016-02-29 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2014-10-01 | Iniziato | MLV & Co | Buy |
| 2014-07-22 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
Charles Schwab Investment Management Inc. Has $136,000 Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
ATNM stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
My Top 2 Stock Picks For A 2025 Rebound - Seeking Alpha
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes - TipRanks
Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress - TipRanks
Actinium Pharma keeps stock target with Buy rating on Q3 earnings - Investing.com UK
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - PR Newswire
HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium: Q3 Earnings Snapshot - mySA
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts - Defense World
Actinium Pharmaceuticals Inc (ATNM) Quarterly 10-Q Report - Quartz
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire
Actinium Pharmaceuticals Appoints June Almenoff to its Board of Directors - citybiz
Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN
The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times
Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR
Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World
Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World
Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN
Wall Street SWOT: Actinium stock rides wave of targeted therapy innovation - Investing.com
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Finansavisen - Finansavisen
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Clinical Trials Arena
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals - ShareCafe
Before Buying Anterix Inc (NASDAQ: ATEX) Stock, Read This First - Stocks Register
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Stock Analysts’ Downgrades for September 18th (ATNM, BHR, CALX, FITB, MEDP, MMSI, MOH, MTRX, NPK, PRMW) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
ATNM: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Actinium Pharmaceuticals Inc (ATNM) requires closer examination - US Post News
Actinium Pharmaceuticals Inc Azioni (ATNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):